Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Executive Summary
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.
You may also be interested in...
Top M&A Of 2016: Cast Your Vote!
It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss
Losing Medivation could end up being a winning proposition for the French pharma if it can boost its cancer franchise another way, like by acquiring its partner in multiple collaborations Regeneron or making a less expensive takeout, such as Incyte or Ariad.
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
The competitive bidding process for Medivation shows just how much big pharma is willing to pay for commercial-stage oncology assets. Now that Pfizer has won the biotech, it will have to prove Xtandi is worth the price.